Q3 2018 13F Holders as of 9/30/2018
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
96M
-
Number of holders
-
170
-
Total 13F shares, excl. options
-
49.8M
-
Shares change
-
+949K
-
Total reported value, excl. options
-
$3.8B
-
Value change
-
+$72.5M
-
Put/Call ratio
-
0.43
-
Number of buys
-
80
-
Number of sells
-
-69
-
Price
-
$76.34
Significant Holders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) as of Q3 2018
190 filings reported holding RARE - Ultragenyx Pharmaceutical Inc. - COMMON STOCK as of Q3 2018.
Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) has 170 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 49.8M shares
of 96M outstanding shares and own 51.85% of the company stock.
Largest 10 shareholders include Capital Research Global Investors (5.86M shares), WELLINGTON MANAGEMENT GROUP LLP (5.27M shares), Capital International Investors (4.36M shares), BlackRock Inc. (4.35M shares), Vanguard Group Inc (4.05M shares), FMR LLC (3.33M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.78M shares), STATE STREET CORP (1.71M shares), FEDERATED INVESTORS INC /PA/ (1.48M shares), and Capital World Investors (1.46M shares).
This table shows the top 170 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.